SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):249P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Hanaoka, K.
Right arrow Articles by Okada, M.
PubMed
Right arrow Articles by Hanaoka, K.
Right arrow Articles by Okada, M.

General Clinical Specialties: General Practice-Oncology

General Practice-Oncology Posters

FDG uptake in bone marrow after G-CSF administration in patients with malignant lymphoma

Kouhei Hanaoka1, Makoto Hosono1, Kimio Usami1, Yuzuru Yamazoe1, Mitsugu Sumita1, Yoshihiro Komeya1, Norio Tsuchiya1, Im Sung-Woon1 and Masahiro Okada1

1 PET, Kinki Univ., Osaka-Sayama, Japan

1065

Objectives: To clarify change over time of FDG uptake after G-CSF, we evaluated the relationship between the interval from the last day of administration of G-CSF to the PET/CT study(interval) and the bone marrow accumulations in patients (pts) with lymphoma.

Methods: Consecutive 67 pts with confirmed malignant lymphoma who underwent FDG PET at the interval within 60 days between January and December 2007 were enrolled. Thirty control subjects without bone marrow lesion who had not received chemotherapy or G-CSF were also included to evaluate 'normal' FDG uptake. PET/CT studies were retrospectively reviewed and maximum SUV(SUVmax) was measured by placing volumetric regions of interest over each thoracic and lumbar vertebra on PET images referring to CT images. Bone marrow SUV was defined as a mean of SUVmax of 12 thoracic and 5 lumbar:SUV(T+L), SUVmax of 12 thoracic:SUV(T), and SUVmax of 5 lumbar vertebrae:SUV(L). The correlation between interval and bone marrow SUV was plotted and analyzed with polynomial approximation.

Results: In the control pts, bone marrow SUV corresponded to 1.86±0.31, 1.82±0.28 and 1.92±0.42 for SUV(T+L), SUV(T), and SUV(L). Among 67 pts with lymphoma, only 7 had bone marrow SUV of >3 and all of them underwent PET/CT at the interval of within 5 days. The polynomial approximation applied to interval and bone marrow SUV suggested that SUV(T+L), SUV(T), and SUV(L) declined to the 'normal' range, i.e., mean+1SD of control pts, at 7.4, 7.2, and 6.5 days, after G-CSF administration in pts with lymphoma. SUV(T+L) presented within 'normal' range at 8 days or later of G-CSF administration in 84%(38 of 45) of the pts.

Conclusions: An interval of at least 8-day is recommended in order to minimize the influence of G-CSF to bone marrow when evaluating treatment response in pts with lymphoma.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Hanaoka, K.
Right arrow Articles by Okada, M.
PubMed
Right arrow Articles by Hanaoka, K.
Right arrow Articles by Okada, M.